Novartis ADR Aktie News

East Hanover, December 12, 2025 – Novartis, a leading global innovative medicines company, broke ground yesterday on its more than 700,000-square-foot flagship manufacturing hub in North Carolina, moving rapidly to construct its recently announced investment in the state.

Basel, December 9, 2025 – Novartis today announced positive results from VAYHIT2, a Phase III trial evaluating ianalumab plus eltrombopag in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids1 -3. Ianalumab (9 mg/kg) plus eltrombopag extended ITP disease control by 45%, based on the primary endpoint of time to treatment failure (TTF), which assesses how ...

Basel, December 9, 2025 – Novartis today announced results showing that one in four patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) remained progression-free for four or more years following treatment with Kisqali® (ribociclib) plus endocrine therapy (ET)1. Results were from a pooled, post-hoc exploratory analys...

LONDON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Relation today announced a multi-program, strategic collaboration with Novartis to discover and advance novel targets for atopic diseases. Under the terms of the agreement, Relation will receive $55 million, comprising an upfront payment, equity investment and additional R&D funding.

The biotech sector began December with notable weakness, as both IBB and XBI ETFs declined over two percent during trading on Monday.  The sector has bounced back since. However, small biotech stocks have been on a huge run since mid-September, due primarily to a notable uptick in M&A activity across the industry. Numerous small and midcap biotech/biopharma stocks have been purchased for signif...

Novartis AG (NVS) Discusses Social Impact, Global Health Initiatives, and Sustainability Strategy Transcript

It earned FDA approval for a spinal muscular atrophy drug. This is a version of its existing commercialized SMA treatment, Zolgensma.

Novartis said on Tuesday up to 550 full-time jobs could be cut by the end of 2027 at the Swiss pharmaceutical company's Stein facility near Basel in northern Switzerland.